Tokyo, Apr 5, 2012 (JCN Newswire) - Eisai Co. Ltd announced today that its U.K. subsidiary Eisai Europe Limited has entered into an agreement with PharmaSwiss S.A., a Division of Valeant Pharmaceuticals International, Inc., to promote and distribute the company's novel anticancer agent Halaven (eribulin mesylate) in a number of Central and Eastern European (CEE) countries.
